Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463848 · ClinicalTrials.gov registry record · Phase 2
Surgical Pembro +/- Olaparib w TMZ for rGBM
A Phase 2 study of Glioblastoma and Recurrent Glioblastoma, sponsored by L. Nicolas Gonzalez Castro, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 4
- Study locations
NCT05463848 is a Phase 2 study of Glioblastoma and Recurrent Glioblastoma that is actively recruiting participants, run by L. Nicolas Gonzalez Castro, MD, PhD. The registered enrollment target is 78 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (28% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT05463848, a Phase 2 study of Glioblastoma and Recurrent Glioblastoma, is actively recruiting participants, sponsored by L. Nicolas Gonzalez Castro, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: * Pembrolizumab * Olaparib * Temozolomide (Temodar)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Olaparib
- DRUG Temozolomide
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2022-10-21 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05463848
The ClinicalTrials.gov registry entry for NCT05463848 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (28% lower). The listed sponsor is L. Nicolas Gonzalez Castro, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05463848 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05463848 about?
NCT05463848 is a clinical study titled "Surgical Pembro +/- Olaparib w TMZ for rGBM". This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: * Pembrolizumab * Olaparib * Temozolomide (Tem...
What is the current status of trial NCT05463848?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2022-10-21. Estimated completion is 2027-03-01.
What conditions does trial NCT05463848 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma.
What interventions are being tested in trial NCT05463848?
The interventions under investigation include: Pembrolizumab (DRUG), Olaparib (DRUG), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT05463848?
This trial is sponsored by L. Nicolas Gonzalez Castro, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05463848 being conducted?
This trial has 4 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
-
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.